RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Shanghai Zhimeng Biopharma started first-in-human dosing of its novel, investigational HBV capsid formation inhibitor in a US Phase I trial. Zhimeng is developing ZM-H1505R for chronic HBV infection. Unlike core protein allosteric modulators, ZM-H1505R is a novel pyrazole molecule with a new binding site in the HBV core protein that inhibits HBV replication. The company expects the candidate will be a cure for HBV, not a treatment. Immediately following this trial, Zhimeng plans to start a China clinical study of ZM-H1505R in HBV-infected patients.
Source: China Biotoday
